Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
34
datasets available to search
ShareScore release 0.9.0
Dataset results
34 results for “immune-related adverse event”
Imaging mass cytometry analysis of brain tissues with CNS immune-related adverse events during anti-PD-1 cancer immunotherapy
<p><span>Dataset accompanying the manuscript "Anti-PD-1 cancer immunotherapy induces CNS immune-related adverse events by Spleen tyrosine kinase activation in microglia".</span></p> <p><span>The Metadata.xls file includes the metadata, the raw image data is saved as .txt file, the segmented cellular expression data is available as csv files. </span></p>
Proteomic and Metabolomic Profiling of Plasma Predict Immune-related Adverse Events in Older Patients with Advanced Non-small Cell Lung Cancer
Open the record for dataset details and reuse information.
Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype
ClinicalTrials.gov study NCT05700565. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
ClinicalTrials.gov study NCT05414552. IPD Sharing: YES. Countries: 1. Publications: 2.
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
ClinicalTrials.gov study NCT04283539. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Fecal calprotectin as a predictor of gastrointestinal immune-related adverse events (CF-19): A prospective study - Excel data and supplementary tables
<p class="cuerpo"><b>Background: </b>Colitis is a frequent immune-related toxicity, without any biomarker that may predict its onset. It is endoscopically similar to intestinal inflammatory diseases, where fecal calprotectin (FC) is used as a biomarker to early-detect a relapse. We found contradictory evidence about FC and immunotherapy and no prospective study was already published. </p> <p class="cuerpo"><b>Methods:</b> We present an analytical, observational and prospective study of one year's duration. We analyzed FCbasal, and then prior to each cycle until the sixth, ending with quarterly follow-up. For evaluating the predictive value of FC we estimated the area under the ROC curve for basal absolute values and for each cycle, and calculated its relative percentage change with respect to basal. We also planned to estimate sensitivity, specificity and predictive values indexes for different cut-off points. Because of lack of recruitment we did a preliminary analysis at the end of the initially estimated period before suggesting its prolongation. </p> <p class="cuerpo"><b>Results:</b> 24 patients were included (19 male), diagnosed from lung cancer (n=15), head and neck, renal, bladder and colorectal cancer (n=2, each), melanoma (n=1). They were treated with Anti PD-1/PDL-1 mono therapy (n=18), combo with chemo (n=2), or combo with anti-CTLA4 (n=2). Three patients had G1 colitis and two, >=G2, all treated with anti-PD1 and before 6th cycle, as described on literature. ROC curve presents AUC 0,559 (CI95%:0,32-0,798) and RR for colitis taking FC value is 1,001 for each 10 units (p=0,493).</p> <p class="cuerpo"><b>Conclusion:</b> Even though we must take into account the limitations of the study we cannot conclude that FC could be used as a predictor for detecting immune-mediated colitis. </p>
Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibitors
ClinicalTrials.gov study NCT07357636. IPD Sharing: YES. Countries: 1. Publications: 0.
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
ClinicalTrials.gov study NCT04115410. IPD Sharing: Not stated. Countries: 0. Publications: 9.
Fecal calprotectin as a predictor of gastrointestinal immune-related adverse events (CF-19): A prospective study - Excel data and supplementary tables
Open the record for dataset details and reuse information.
Immune-related cutaneous adverse events display distinct clinical and molecular characteristics, depending on immune checkpoints targeted
GEO Series GSE297863. Homo sapiens. 32 samples. Type: Expression profiling by high throughput sequencing.
Inhibition of IL-17A Protects against Thyroid Immune-related Adverse Events while Preserving Checkpoint Inhibitor Anti-tumor Efficacy [RNA-seq (murine)]
GEO Series GSE176561. Mus musculus. 5 samples. Type: Expression profiling by high throughput sequencing.
Multiomics analysis of immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors
GEO Series GSE227001. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Single cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors
GEO Series GSE216329. Homo sapiens. 48 samples. Type: Expression profiling by high throughput sequencing.
CD4+ T-Cells Mediate CART Immune-Related Adverse Events (CirAE) Following BCMA CART Therapy
GEO Series GSE309403. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
Montreal Immune-Related Adverse Events (MIRAE) Study
ClinicalTrials.gov study NCT05139706. IPD Sharing: YES. Countries: 1. Publications: 0.
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
ClinicalTrials.gov study NCT04375228. IPD Sharing: NO. Countries: 1. Publications: 0.
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
ClinicalTrials.gov study NCT06089967. IPD Sharing: NO. Countries: 1. Publications: 0.
Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs)
ClinicalTrials.gov study NCT05675111. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Investigational Biomarkers for Neurological Immune-related Adverse Events
ClinicalTrials.gov study NCT05969379. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors
ClinicalTrials.gov study NCT05544292. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.